← Leaderboards
Timothy Eoin West
University Of Washington
$8,695,820
Attributed
$15,488,730
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,488,730 · 12
By mechanism
R01$10,043,392 · 3
R21$2,771,819 · 7
U01$2,036,319 · 1
K08$637,200 · 1
Top collaborators
- Sina A Gharib11 shared
- Narisara Chantratita10 shared
- Shawn J. Skerrett9 shared
- Patrick S. Stayton7 shared
- Daniel M. Ratner5 shared
- Sandra Schwarz2 shared
- Courtney Crane1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Grace C John-Stewart$42,921,726
- Jairam Rao Lingappa$17,018,282
- Shawn J. Skerrett$5,911,130
- Kristina M Adams Waldorf$20,913,441
- Andrew Atwell Oberst$17,614,781
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionMelioidosisBurkholderia PseudomalleiBacterial InfectionsPneumoniaPublic HealthCellsSepsisLungSoilPathway InteractionsMortalityPathogenResearch PersonnelBloodImmune ResponseInflammatory ResponseThailandIngestionAlveolar MacrophagesNovel TherapeuticsCessation Of LifeInhalationPhenotype
Grant awards (41)
Combination host-directed and antibacterial therapy for pulmonary intracellular infections$760,910
R01 · FY2025 · AI
A plasma proteomic diagnostic for melioidosis$166,312
R21 · FY2025 · AI · contact PI
A plasma proteomic diagnostic for melioidosis$44,280
R21 · FY2025 · AI · contact PI
A plasma proteomic diagnostic for melioidosis$19,278
R21 · FY2025 · AI · contact PI
Combination host-directed and antibacterial therapy for pulmonary intracellular infections$738,160
R01 · FY2024 · AI
Multi-omics of murine respiratory melioidosis$194,375
R21 · FY2024 · AI · contact PI
A plasma metabolite diagnostic for melioidosis$179,128
R21 · FY2024 · AI · contact PI
Multi-omics of murine respiratory melioidosis$233,250
R21 · FY2023 · AI · contact PI
A plasma metabolite diagnostic for melioidosis$219,765
R21 · FY2023 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$633,062
R01 · FY2022 · AI
Integrated Multi-omics of Melioidosis$758,287
R01 · FY2021 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$583,781
R01 · FY2021 · AI
Genetically engineered macrophages to treat pulmonary infections$216,942
R21 · FY2021 · AI · contact PI
Integrated Multi-omics of Melioidosis$864,642
R01 · FY2020 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$512,525
R01 · FY2020 · AI
Genetically engineered macrophages to treat pulmonary infections$276,097
R21 · FY2020 · AI · contact PI
Interaction of the Burkholderia type VI secretion system with innate host defenses$163,804
R21 · FY2020 · AI · contact PI
Integrated Multi-omics of Melioidosis$871,221
R01 · FY2019 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$493,087
R01 · FY2019 · AI
Determinants of Outcome and Recurrent Infections in Melioidosis$402,057
U01 · FY2019 · AI
Interaction of the Burkholderia type VI secretion system with innate host defenses$217,375
R21 · FY2019 · AI · contact PI
B. pseudomallei infection of the human lung$188,048
R21 · FY2019 · AI · contact PI
Integrated Multi-omics of Melioidosis$750,994
R01 · FY2018 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$493,126
R01 · FY2018 · AI
Determinants of Outcome and Recurrent Infections in Melioidosis$408,903
U01 · FY2018 · AI
B. pseudomallei infection of the human lung$226,519
R21 · FY2018 · AI · contact PI
Cellular GWAS of the host-pathogen interaction in melioidosis$194,271
R21 · FY2018 · AI · contact PI
Determinants of Outcome and Recurrent Infections in Melioidosis$408,352
U01 · FY2017 · AI
Cellular GWAS of the host-pathogen interaction in melioidosis$232,375
R21 · FY2017 · AI · contact PI
Determinants of Outcome and Recurrent Infections in Melioidosis$408,413
U01 · FY2016 · AI
Regulation of host inflammatory responses and outcome in melioidosis by TLR5$320,958
R01 · FY2016 · HL · contact PI
Regulation of host inflammatory responses and outcome in melioidosis by TLR5$472,641
R01 · FY2015 · HL · contact PI
Determinants of Outcome and Recurrent Infections in Melioidosis$408,594
U01 · FY2015 · AI
Regulation of host inflammatory responses and outcome in melioidosis by TLR5$635,696
R01 · FY2014 · HL · contact PI
Regulation of host inflammatory responses and outcome in melioidosis by TLR5$573,608
R01 · FY2013 · HL · contact PI
Pulmonary Pathogen-Recognition Pathways in Melioidosis$127,440
K08 · FY2013 · HL · contact PI
Regulation of host inflammatory responses and outcome in melioidosis by TLR5$580,694
R01 · FY2012 · HL · contact PI
Pulmonary Pathogen-Recognition Pathways in Melioidosis$127,440
K08 · FY2012 · HL · contact PI
Pulmonary Pathogen-Recognition Pathways in Melioidosis$127,440
K08 · FY2011 · HL · contact PI
Pulmonary Pathogen-Recognition Pathways in Melioidosis$127,440
K08 · FY2010 · HL · contact PI
Pulmonary Pathogen-Recognition Pathways in Melioidosis$127,440
K08 · FY2009 · HL · contact PI